Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00223678
Status:
COMPLETED
Last Update Posted:
2017-06-21
First Post:
2005-09-19
Brief Title:
Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Sponsor:
Vanderbilt University Medical Center
Organization:
Vanderbilt University Medical Center
Study Overview
Official Title:
Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A study to determine the effect on renal function in renal transplant patients with biopsy proven Chronic allograft nephropathy CAN nephropathy who are switched from a Calcinerin inhibitor CI triple drug regimen to a Rapamycin based triple drug regimen or maintained on their CI protocol
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None